Table 1.
Observed Percentages of Human CD45+ Cells at 12-Weeks Postxenograft or Serial Transplant in Hematopoietic Compartments of Nonirradiated Mice
| Location | Marker (Cell) | NSG (%) | NBSGW (%) |
|---|---|---|---|
| Peripheral Blood | CD3+ (lymphoid, T cell) | 3.1 ± 2.0 | 3.3 ± 1.5 |
| CD19+ (lymphoid, B cell) | 46.4 ± 3.2 | 68.4 ± 2.9∗ | |
| CD11b+ (myeloid) | 3.4 ± 1.4 | 2.5 ± 0.5 | |
| CD15+ (Neut, Eos, Mono) | 2.4 ± 2.2 | 1.4 ± 0.2 | |
| CD66b+ (Gran) | 2.5 ± 1.5 | 2.1 ± 0.3 | |
| Bone Marrow | CD3+ (lymphoid, T cell) | 3.5 ± 0.5 | 5.4 ± 1.0 |
| CD19+ (lymphoid, B cell) | 86.0 ± 2.0 | 89.0 ± 1.1 | |
| CD19+IgM+ (lymphoid, B cell) | 0.3 ± 0.1 | 0.5 ± 0.1 | |
| Spleen | CD3+ (lymphoid, T cell) | 3.6 ± 1.5 | 3.0 ± 1.5 |
| CD56low/+ (NKT cell) | 0.8 ± 0.3 | 1.0 ± 0.3 | |
| Secondary Graft | CD3+ (lymphoid, T cell) | ND | 0.3 ± 0.6 |
| Peripheral Blood | CD19+ (lymphoid, B cell) | ND | 87.8 ± 4.6 |
| CD11b+ (myeloid) | ND | 8.5 ± 6.5 |
Error is represented by SD (n = 5, ∗p < 0.01). Eos, eosinophil; Gran, granulocyte; Mono, monocyte; ND, not determined; Neut, neutrophil.